Advanced search
Publication Cover
Breast Cancer: Targets and Therapy Volume 15, 2023 - Issue
Submit an article Journal homepage
377
Views
1
CrossRef citations to date
0
Altmetric
CASE REPORT

Rhabdomyolysis Induced by the Interaction Between Ribociclib and Statins- Case Report and Literature Review

Omar Badran1 Department of Oncology, Emek Medical Center, Afula, IsraelORCID Iconhttps://orcid.org/0000-0001-6712-0291
ORCID Icon,
Mahmoud Abu Amna1 Department of Oncology, Emek Medical Center, Afula, Israel;2 Technion Integrated Cancer Center, Faculty of Medicine, Technion, Haifa, Israel
,
Ilit Turgeman1 Department of Oncology, Emek Medical Center, Afula, Israel
&
Gil Bar-Sela1 Department of Oncology, Emek Medical Center, Afula, Israel;2 Technion Integrated Cancer Center, Faculty of Medicine, Technion, Haifa, IsraelCorrespondence[email protected]
Pages 47-50 | Received 10 Sep 2022, Accepted 07 Jan 2023, Published online: 24 Jan 2023

References

  • Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A. Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs. 2021;81:317–331. doi:10.1007/S40265-020-01461-2
  • Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738–1748. doi:10.1056/NEJMOA1609709
  • Tripathy D, I’m SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomized Phase 3 trial. Lancet Oncol. 2018;19:904–915. doi:10.1016/S1470-2045(18)30292-4
  • Slamon DJ, Neven P, Chia S, et al. Corrigendum to “Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in phase III randomized MONALEESA-3 trial: updated overall survival”: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015–1024]. Ann Oncol. 2021;32:1307. doi:10.1016/j.annonc.2021.07.011
  • Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386:942–950. doi:10.1056/NEJMOA2114663
  • Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clin Cancer Res. 2017;23:3251–3262. doi:10.1158/1078-0432.CCR-16-3157/274469/AM/RIBOCICLIB-LEE011-MECHANISM-OF-ACTION-AND-CLINICAL
  • Trialists CT. (CTT) collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet. 2005;366:1267–1278. doi:10.1016/S0140-6736(05)67394-1
  • Fulcher J, O’Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: a meta-analysis of individual data from 174,000 participants in 27 randomized trials. Lancet. 2015;385:1397–1405. doi:10.1016/S0140-6736(14)61368-4
  • Strandberg TE, Pyörälä PK, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up Scandinavian Simvastatin Survival Study (4S). Lancet. 2004;364:771–777. doi:10.1016/S0140-6736(04)16936-5
  • Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–1308. doi:10.1056/NEJM199511163332001
  • Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J Clin Med. 2019;9(1):22. doi:10.3390/JCM9010022
  • Tomaszewski M, Stȩpień KM, Tomaszewska J, Czuczwar SJ. Statin-induced myopathies. Pharmacol Rep. 2011;63:859–866. doi:10.1016/S1734-1140(11)70601-6
  • Torres PA, Helmstetter JA, Kaye AM, Kaye AD. Rhabdomyolysis: pathogenesis, Diagnosis, and Treatment. Ochsner J. 2015;15:58.
  • Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19:117–125. doi:10.1111/J.1472-8206.2004.00299.X
  • Nelson KL, Stenehjem D, Driscoll M, Gilcrease GW. Fatal statin-induced rhabdomyolysis by possible interaction with palbociclib. Front Oncol. 2017;7:7. doi:10.3389/FONC.2017.00150
  • Nersesjan V, Hansen K, Krag T, Duno M, Jeppesen TD. Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report. BMC Neurol. 2019;19. doi:10.1186/S12883-019-1490-4
  • Streicher C, Daulange A, Madranges N, Vayre L. Severe rhabdomyolysis induced by possible drug-drug interaction between Ribociclib and Simvastatin. J Oncol Pharm Pract. 2021;27:722–726. doi:10.1177/1078155220945365
  • CHMP. Committee for medicinal products for human use (CHMP) assessment report; 2017. Available from: https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf. Accessed January 17, 2023.
  • Szadkowska I, Stanczyk A, Aronow WS, et al. Statin therapy in the elderly: a review. Arch Gerontol Geriatr. 2010;50:114–118. doi:10.1016/J.ARCHGER.2008.12.012
  • Curfman G. Risks of statin therapy in older adults. JAMA Intern Med. 2017;177:966. doi:10.1001/JAMAINTERNMED.2017.1457
  • Horodinschi RN, Stanescu AMA, Bratu OG, Stoian AP, Radavoi DG, Diaconu CC. Treatment with Statins in Elderly Patients. Medicina. 2019;55(2):55. doi:10.3390/MEDICINA55110721
  • Stavrou EP, Buckley N, Olivier J, Pearson SA. Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage. BMJ Open. 2012;2:e000880. doi:10.1136/BMJOPEN-2012-000880

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.